The Encephalomyelitis drugs in development market research report provides comprehensive information on the therapeutics under development for Encephalomyelitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Encephalomyelitis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Encephalomyelitis and features dormant and discontinued products.
GlobalData tracks 21 drugs in development for Encephalomyelitis by 20 companies/universities/institutes. The top development phase for Encephalomyelitis is preclinical with 11 drugs in that stage. The Encephalomyelitis pipeline has 17 drugs in development by companies and four by universities/ institutes. Some of the companies in the Encephalomyelitis pipeline products market are: Trethera, Cortene and Paxmedica.
The key targets in the Encephalomyelitis pipeline products market include Sodium Dependent Dopamine Transporter (DA Transporter or DAT or Solute Carrier Family 6 Member 3 or SLC6A3), Soluble Guanylate Cyclase (sGC or EC 4.6.1.2), and Sodium Dependent Noradrenaline Transporter (Norepinephrine Transporter or NET or Solute Carrier Family 6 Member 2 or SLC6A2).
The key mechanisms of action in the Encephalomyelitis pipeline product include Sodium Dependent Dopamine Transporter (DA Transporter or DAT or Solute Carrier Family 6 Member 3 or SLC6A3) Inhibitor with two drugs in Phase II. The Encephalomyelitis pipeline products include five routes of administration with the top ROA being Oral and six key molecule types in the Encephalomyelitis pipeline products market including Small Molecule, and Synthetic Peptide.
Encephalomyelitis overview
Encephalomyelitis is an inflammation of the brain and spinal cord. Encephalomyelitis can be caused by a variety of conditions that lead to irritation of the brain and spinal cord. Among the common causes of encephalomyelitis are viruses which infect the nervous tissues. Signs and symptoms include neck stiffness, headache, and fever. Treatment includes antibiotics and corticosteroids.
For a complete picture of Encephalomyelitis’s pipeline drug market, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
